Results 141 to 150 of about 681,456 (227)

Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]

Clin Ophthalmol
Ploeger CG, Carvalho Soares Valentim C, Guner ME, Kabaalioglu Guner M.   +3 more
europepmc   +1 more source

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review. [PDF]

J Clin Med
Gandhi S, Munro I, Shodimu V, Webb N, Pannagl K, Wiyani A, Balp MM.   +6 more
europepmc   +1 more source

Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead. [PDF]

Indian J Ophthalmol
Mishra C, Mohanty N, Purohit S, Orugonda U, Patil V.   +4 more
europepmc   +1 more source

Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases. [PDF]

BioDrugs
Kumar S, Dalbeth N, Gasteiger C.
europepmc   +1 more source

The FDA's adoption of Bayesian methodology: transforming clinical trial justification from biosimilars to broader drug development. [PDF]

Front Med (Lausanne)
Niazi SK.
europepmc   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review. [PDF]

Health Sci Rep
Ahmed Z, Maha TT, Nowsher S, Taslim W, Fatema-Tuz-Zohora, Sharmin S, Yasmin H.   +6 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [PDF]

Pharmacoecon Open
Rodríguez-Lago I, Peinado-Fabregat JI, Guigini M, Cerezales M, Ibáñez F, Crespo C, Barreiro-de Acosta M.   +6 more
europepmc   +1 more source

Performance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis. [PDF]

Drug Deliv
Moses K S, Konda Ramachary Subramanian S.   +1 more
europepmc   +1 more source

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]

World J Gastroenterol
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.   +10 more
europepmc   +1 more source

Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Ghosh S, Sethi B, Kalra S, Baruah MP, Mane A, Choudhari S, Petare A, Jadhav M, Patil S, Barkate H.   +9 more
europepmc   +1 more source